Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Clinical Evaluator Training Group

Research output: Contribution to journalArticlepeer-review

229 Scopus citations

Fingerprint

Dive into the research topics of 'Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences